US Stocks Move: AbbVie Rises Nearly 2% Pre-market as Major Drug Receives Two New Indications

格隆汇2026/07/29 08:51

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gelonghui, July 29｜AbbVie rose nearly 2% in pre-market trading, at $267.5. AbbVie announced today that the European Commission has approved upadacitinib for two new indications: 1. Treatment of severe alopecia areata in adults and adolescents; 2. Treatment of non-segmental vitiligo in adults and adolescents. AbbVie has already submitted applications for the same indications in China and the United States, which are currently under review. Upadacitinib is a selective JAK inhibitor, already approved globally for indications such as atopic dermatitis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. In 2025, global sales of this product are expected to reach $8.304 billion. Upadacitinib is the first JAK inhibitor to achieve complete scalp hair regrowth compared to placebo at week 24.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

New York Fed official Perli stated that the current scale of reserve management bond purchases is zero, and future adjustments will be made according to "evolving market conditions," in order to implement the policy of keeping reserves within an ample range. The New York Fed will continue to monitor senior financial officials' assessments of market conditions and track signs of stress in the funding markets. Market participants expect a new round of large-scale net issuance of short-term Treasury bills in October.

华尔街见闻•2026/09/23 00:01

After about one month of launch, the Grok Bot AI agent under SpaceX (SPCX.US) has surpassed 400,000 weekly users.

The AI agent product Grok Bot launched by SpaceXAI has surpassed 400,000 weekly users in about a month since its release, indicating a moderate early demand for the product.

智通财经•2026/09/22 23:56

Strategy CEO Phong Le Reveals the One Mistake Behind STRC's 25% Collapse

BeInCrypto•2026/09/22 23:54